Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P890047/S068

PROVISC Ophthalmic Viscosurgical Device

Alcon Research, Ltd. · Decision date Jul 25, 2025

FDA DECISIONP890047/S068

What did the FDA decide?

FDA records P890047/S068 as a supplement to PMA P890047, with the supplement type “30-Day Notice”. The recorded decision is OK30 (30-day notice), dated Jul 25, 2025.

FDA approval order statement

updating the Sodium Hyaluronate raw material testing by the supplier for the VISCOAT Ophthalmic Viscosurgical Device, DUOVISC Ophthalmic Viscoelastic System, DISCOVISC Ophthalmic Viscosurgical Device, and PROVISC Ophthalmic Viscosurgical Device
Regulatory pathway
PMA supplement
Supplement type
30-Day Notice
Clinical specialty
Ophthalmic
Decision date
Jul 25, 2025
FDA change category
Process Change - Manufacturer/Sterilizer/Packager/Supplier

FDA source record

Regulatory record facts

Identifier
P890047/S068
Regulatory pathway
PMA supplement
Product code
LZP
Decision code
OK30
Decision date
Jul 25, 2025
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: AID, SURGICAL, VISCOELASTIC.

Product code
LZP
FDA device class
3

For the original device and its historical approval scope, see PMA P890047. Subsequent supplements may change the device or its indications.

FDA decision timeline

  1. P890047 · Original PMA

    PROVISC(TM)VISCOELASTIC PREPARATION

  2. P890047/S068 received

    Application receipt date recorded by FDA.

  3. P890047/S068 · FDA decision

    30-Day Notice

  4. P890047/S069 · Related supplement

    PROVISC Ophthalmic Viscosurgical Device

  5. P890047/S070 · Related supplement

    PROVISC Ophthalmic Viscosurgical Device

  6. P890047/S072 · Related supplement

    PROVISC Ophthalmic Viscosurgical Device

Timeline entries are records held by MedtechLedger for P890047. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P890047

Product / regulatory recordCompanyPathwayDecision dateSource
Alcon Research, Ltd.PMA approvalSep 26, 1991FDA
Alcon Research, Ltd.PMA supplementOct 3, 2025FDA
Alcon Research, Ltd.PMA supplementAug 4, 2026FDA
Alcon Research, Ltd.PMA supplementOct 1, 2026FDA

Explore the linked device profile

Other records with product code LZP

A shared product code identifies a classification relationship; it does not establish clinical equivalence.

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Alcon Research, Ltd.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
6201 S. Fwy., R3-48, Fort Worth, TX, 76134

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records